Health Day Reporter
Saturday, May 31, 2014 (HealthDay News)-Combination of two new pills could nearly double the survival of relapsed patients Ovarian cancerAccording to the results of preliminary clinical trials.
Treatment is Drug Olaparib and Sedilanib. Dr. Joyce Liu, a gynecological oncologist at Dana-Farber, states that he provided an average progression-free survival of nearly 18 months, as opposed to a 9-month survival with olaparib treatment alone. cancer Boston Institute.
Liu was scheduled to present his findings at the American Clinical Society on Saturday Oncology Meeting in Chicago.
The result is “comparable to what you see chemical treatment“Mr. Liu said. As a result, the combination of this drug is “chemical treatment Alternative for treatment of Ovarian cancer“She said. The patient was able to swallow the tablets rather than administer them intravenously. chemical treatment processing.
4 out of 5 aggressive women Ovarian cancer The researchers said they would experience a recurrence after chemotherapy.when cancer Back, it has spread to other parts of the body and is likely to have developed resistance to chemotherapy.
For this reason, researchers have sought alternative treatments for the ovaries. cancer It can overcome resistance to chemotherapy.
Olaparib works by targeting an enzyme called PARP that repairs DNA damage in cells and can cause it if it is inhibited. cancer Dead cells.Sedilanib blocks the growth of blood vessels tumor, Hungry cancer of Nutrition And the oxygen it needs to survive.
Both Drug According to Liu, it is awaiting approval from the US Food and Drug Administration. Also, like most studies presented at conferences, findings should be considered preliminary until published in a peer-reviewed medical journal.
American people cancer 90 aggressive women participated in the lab-funded trial Ovarian cancer It returned after chemotherapy. Participants were randomly assigned to be treated with olaparib alone or with a combination of olaparib and cedilanib.Everything had cancer Responded to platinum-based chemotherapy.
Tumors shrank more dramatically during combination therapy-80% compared to 48% of patients who received olaparib alone, the researchers found.
The combination therapy slowed the progression of the disease and had a median progression-free survival of 17.7 months, the researchers said. Past trials of standard chemotherapy in platinum-sensitive patients have shown a median progression-free survival of 8 to 13 months, they say.
Five patients in the combination therapy group and two patients in the olaparib alone group showed complete remission.
“The combination of these two agents has significantly improved activity,” says Liu.
The drug seems to have a synergistic effect. In other words, when used together, they will be more effective with each other.
It’s not clear how the drugs work together, Liu said. One theory is that using cediranib to deprive cancer cells of oxygen makes them more vulnerable to DNA damage left unrepaired by olaparib.The other is that both may work to slow the growth of blood vessels. tumor..
The use of both drugs together most commonly increases side effects High blood pressure, Malaise And diarrhea, The researcher said. In most cases, side effects were controlled by treating the symptoms or adjusting the dose of the drug, Liu said.
Dr. David Fishman is a gynecological oncologist at Mount Sinai Hospital and a professor at Mount Sinai School of Medicine in New York City. He called the new discovery “very exciting.”
“We are entering an era of identifying unique pathways for cancer, and treatments that attack the unique biology of cancer are far more effective than ever,” he said. ..
Fishman compared how Gun works to a cross-country road trip that says, “There are many ways to drive from New York City to Portland.” These targeted therapies form obstacles along several major routes, pushing cancer into inefficient sideways with little use.
“This is proof that understanding the biology of a tumor and applying treatments specific to that tumor are effective,” he said.
Copyright © 2014 Health Day. all rights reserved.
Source: Joyce Liu, MD, MPH, Gynecologic Oncologist, Dana-Farber Cancer Institute, Boston. Dr. David Fishman, Ph.D., Gynecological Oncologist, Mount Sinai Hospital, and Professor of Mount Sinai School of Medicine, New York City. May 30, 2014, Presentation Summary, American Society of Clinical Oncology Conference, Chicago
A pair of tablets indicates the possibility of recurrent ovarian cancer
Source link A pair of tablets indicates the possibility of recurrent ovarian cancer